MSD and Pfizer received convincing results of CI of hypoglycemic drug

news

MSD and Pfizer successfully conducted two Phase III clinical trials hypoglycemic drugs, ertugliflozin (ertugliflozin). Within the CI, the experimental drug was used in combination with sitagliptin or metformin.
According to the results of the VERTIS MET clinical study, after 26 weeks of therapy, A1C hemoglobin level decreased by 0.7% and 0.9% in patients receiving metformin and ergogliflozin at a dosage of 5 mg and 15 mg, respectively. In the group of patients who did not receive the experimental drug,the A1C level did not decrease at all. This study included only patients who did not respond to metformin therapy. The authors of CI also note that in the group of ertugliflozin a significantly larger number of patients have reached A1C level below 7%.
In the second clinical trial of VERTIS SITA, participants received ergugliflozin (5 mg or 15 mg) in combination with sitagliptin (100 mg) or placebo. In the active treatment group, A1C level reduction was 1.6% and 1.7% (for 5 mg and 15 mg of ergouflofosin, respectively), compared with 0.4% in the placebo group.
Ertugliflozin is an oral inhibitor of SGLT-2. The sodium glucose cotransporter system (SGLT) in the kidneys plays an important role in maintaining the overall balance of glucose in the body. Normally, the kidneys filter about 180 g of glucose every day, and almost all of this amount is absorbed back into the bloodstream. Glucose reabsorption takes place in the proximal tubule of the kidneys using the SGLT system. Selective inhibition of SGLT type 2 through an insulin-independent mechanism of action provides removal of excess glucose from the body and the excess calories in it with urine, thereby reducing blood glucose levels.

A source:

Remedium